Skip to content

Dott.ssa Lioi Susanna

Ortottista / Assistente in Oftalmologia
Dott.ssa Lioi Susanna

Linea di ricerca:

Unità di ricerca:

Attività medica: attività clinico scientifica nell’Unità Operativa di ricerca “Retina Medica” presso l’IRCCS Fondazione G.B. Bietti nelle sedi di Via Livenza, 3 e  in Via di santo Stefano Rotondo 6, presso Presidio Ospedaliero Britannico, Roma 

Profilo linkedin: Susanna Lioi

E-mail: susanna.lioi@fondazionebietti.it

  • 2009 Laurea con lode in Ortottica e assistenza oftalmologica, presso l’Università di Roma Tor Vergata 
  • 2010 – 2012: Borsista Linea di Ricerca Retina medica 
  • 2013 – 2015: Contrattista Linea di Ricerca Retina medica 
  • 2016 – oggi: Dipendente a tempo indeterminato  
  • Strutturato presso IRCCS Fondazione G.B.Bietti, Divisione Retina Medica 

Clinical Trial Experience 

  • A Clinical Safety and Efficacy Comparison of  NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients (MIZAR )  Co-Investigator 
  • Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema (RETAIN).  Co-investigator. 
  • A 12-Month, multicenter, randomized, parallel group study to compare the efficacy and safety of Ozurdex versus Lucentis in patients with branch retinal vein occlusion.( COMO ) Study-coordinator 
  • A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema (VIVID).  study-coordinator. 
  • A6-month,Phase II, Double-masked, Multicenter, Randomized,Placebo- controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice  Daily for the Treatment of Center- involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy . (FOVEA) Co-investigator. 
  •  
  • A multicentric open-label randomized study comparing the efficacy and safety of 700  g dexamethasone segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema  
  • (LUZO) Co-investigator 
  •  
  • A 12-month, phase IIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration ( TREND) Study-coordinator 
  •  
  • A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)  (MINERVA) Study- coordinator 
  • A PHASE 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of fovista ( anti pdgf-b pegylated aptamer) administered in combination with Lucentis compared to lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration. ( Fovista-OPH1002 ) Study-coordinator 
  • A Phase II multicenter, randomizes, double-maskerd, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patents with geographic atrophy secondary to o age-related macular degeneration. (CHROMA) Study coordinator  
  • A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy. Fovista-OPH1004)   Study coordinator  
  • Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration. (SEQUOIA) Co-investigator 
  • An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and  tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment  regimens to subjects with neovascular age-related macular degeneration (nAMD). (AZURE) Co-investigator 
  • Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept – a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study. (ARIES)  Co-investigator 
  • A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion . (CENTERA)  Co-investigator 
  • Development of novel clinical endpoints for interventional clinical trials with a regulatory and patients access intension in patients with intermediate Age related macular degeneration  (MACUSTAR)   Study coordinator  
  • A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with Non-proliferative diabetic retinopathy without center-involved diabetic macular edema.  (ROBIN study) Study-coordinator 
  • Studio di fase III, multicentrico, randomizzato, in doppio  cieco, a tre bracci di trattamento, della durata di due anni  per valutare l’efficacia e la sicurezza di brolucizumab verso aflibercept in pazienti adulti con diminuzione visiva causata da edema maculare diabetico. 
  •  (KESTREL)  Study-coordinator 
  • Evidence of Anti-VEGF use in real Life Experience – A retrospective cohort study from secondary data source in Italy – Chart Review . (EAGLE) Study-coordinator 
  • Studio multicentrico, in doppio cieco, randomizzato, doseranging volto a valutare l’efficacia e la sicurezza di conbercept per iniezione intravitreale in soggetti affetti da degenerazione maculare legata all’età neovascolare (PANDA) Study-coordinator 
  • An observetional study program to investigate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion .in areal world setting.(AURIGA)  Study-coordinator 
  • Valutazione di un regime di dosaggio prolungato e proattivo in pazienti naïve al trattamento con degenerazione maculare senile umida, wamd.(XTEND) study-coordinator 
  • Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion.(RAPTOR)  Co-investigator 
  • Study to Gather Information on Safety and Use of High Dose Aflibercept Injection Into the Eye in Patients With an Age Related Eye Disorder That Causes Blurred Vision or a Blind Spot Due to Abnormal Blood Vessels That Leak Fluid Into the Light Sensitive Lining Inside the Eye. (PULSAR) Co-investigator 
  • Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia  (Recognised) Study coordinator 
  • Patient Experience and Preference (PEP) Study in nAMD and DME. Study Protocol – MR41928  
  • (PEP STUDY)  Study coordinator 
  • A longitudinal, biomarker study of anti-vegf, to explore the relationship between aqueous humor composition and multimodal retinal imaging in neovascular age-related macular degeneration and diabetic macular edema  (LONGITUDE)  Study coordinator 
  • Valutazione della soddisfazione del paziente nella gestione della degenerazione maculare legata all’età in forma umida (wet Age-Related Macular Degeneration – wAMD): survey sui pazienti italiani . (Studio SWAN)  Study coordinator 
  • Rwe study of anti-vegf therapies in neovascular age related macular degeneration in Italy : adherence, needs,cost and effectiveness analysis. (Studio ML 43 667 Radiance) Study coordinator 

 

Skip to content